Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Efficacy and Safety in MDD
NCT00735709Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Started Aug 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00735709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00735709.